In a report issued Tuesday May 13th, HSBC upgraded the rating on Qiagen QGEN from Underweight to Neutral with a target price of €17.00.
HSBC analyst Jan Keppeler anticipates Qiagen's better research budget funding should help the company hit the 2014 4-5 percent sales growth target.
While Keppeler does not see Qiagen as a “bargain,” she does see the risk much more limited than previously anticipated.
On the NASDAQ, shares of Qiagen last traded at $22.39, down about 0.5 percent despite the HSBC upgrade.
Market News and Data brought to you by Benzinga APIs© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Comments
Loading...
date | ticker | name | Price Target | Upside/Downside | Recommendation | Firm |
---|
Benzinga simplifies the market for smarter investing
Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.
Join Now: Free!
Already a member?Sign in